Shares of OptimizeRx Corp. (NASDAQ:OPRX – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the nine analysts that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the company. The average 12 month price target among analysts that have covered the stock in the last year is $11.21.
A number of research analysts have recently weighed in on OPRX shares. Citigroup reissued a “market outperform” rating on shares of OptimizeRx in a research report on Tuesday, October 27th. Weiss Ratings upgraded shares of OptimizeRx from a “sell (d)” rating to a “sell (d+)” rating in a research note on Tuesday, August 25th. Lake Street Capital lowered their price target on shares of OptimizeRx from $11.00 to $10.00 and set a “buy” rating on the stock in a report on Thursday. Stifel Nicolaus decreased their target price on OptimizeRx from $12.00 to $11.00 and set a “buy” rating for the company in a research report on Thursday. Finally, Wall Street Zen downgraded OptimizeRx from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 20th.
View Our Latest Analysis on OptimizeRx
OptimizeRx Price Performance
OPRX stock opened at $7.34 on Monday. The stock’s fifty day simple moving average is $8.43 and its two-hundred day simple moving average is $7.20. The company has a current ratio of 5.06, a quick ratio of 5.58 and a debt-to-equity ratio of 0.09. OptimizeRx has a 1-year low of $4.54 and a 1-year high of $15.59. The stock has a market cap of $138.29 million, a P/E ratio of 29.36 and a beta of 1.20.
OptimizeRx (NASDAQ:OPRX – Get Free Report) last announced its quarterly earnings data on Wednesday, November 11th. The company reported $0.20 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.16 by $0.04. The firm had revenue of $21.61 million during the quarter, compared to the consensus estimate of $21.19 million. OptimizeRx had a return on equity of 9.58% and a net margin of 5.33%. Analysts expect that OptimizeRx will post 0.49 EPS for the current year.
Hedge Funds Weigh In On OptimizeRx
A number of large investors have recently made changes to their positions in the stock. Royce & Associates LP lifted its holdings in OptimizeRx by 20.7% during the 3rd quarter. Royce & Associates LP now owns 1,315,057 shares of the company’s stock worth $10,981,000 after purchasing an additional 225,659 shares in the last quarter. Mink Brook Asset Management LLC raised its stake in shares of OptimizeRx by 254.4% during the third quarter. Mink Brook Asset Management LLC now owns 500,483 shares of the company’s stock worth $4,179,000 after acquiring an additional 359,248 shares in the last quarter. Marshall Wace LLP lifted its stake in shares of OptimizeRx by 183.2% in the 3rd quarter. Marshall Wace LLP now owns 459,362 shares of the company’s stock valued at $3,836,000 after acquiring an additional 297,176 shares during the last quarter. Rice Hall James & Associates LLC boosted its position in OptimizeRx by 1.9% during the 1st quarter. Rice Hall James & Associates LLC now owns 601,921 shares of the company’s stock valued at $3,780,000 after buying an additional 11,247 shares during the period. Finally, Dimensional Fund Advisors LP lifted its holdings in OptimizeRx by 22.3% in the 1st quarter. Dimensional Fund Advisors LP now owns 563,570 shares of the company’s stock worth $3,540,000 after buying an additional 102,661 shares during the period. 76.47% of the stock is owned by institutional investors.
About OptimizeRx
OptimizeRx is a healthcare technology company that connects life sciences companies with healthcare professionals and patients through digital communications. Its platform uses channels such as electronic health records and other clinical workflows to deliver relevant information at the point of care. The company’s services support programs for medication access and affordability, patient education and engagement, and communication between healthcare providers and life sciences organizations. OptimizeRx also provides tools intended to help life sciences companies reach clinicians and patients through digital channels.
Recommended Stories
- Five stocks we like better than OptimizeRx
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for OptimizeRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptimizeRx and related companies with MarketBeat.com's FREE daily email newsletter.
